Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novagali Pharma |
---|---|
Information provided by: | Novagali Pharma |
ClinicalTrials.gov Identifier: | NCT00739349 |
Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.
Condition | Intervention | Phase |
---|---|---|
Dry Eye |
Drug: NOVA22007 ''Cyclosporine'' Drug: NOVA22007 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Multi-Center, Double-Masked, Randomized Study of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions Compared to Vehicle for the Treatment of the Signs and Symptoms of Dry Eye |
Estimated Enrollment: | 129 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Cyclosporine 0.05%
|
Drug: NOVA22007 ''Cyclosporine''
Cyclosporine 0.05% Ophthalmic Cationic Emulsions
|
2: Experimental
Cyclosporine 0.1%
|
Drug: NOVA22007 ''Cyclosporine''
Cyclosporine 0.1% Ophthalmic Cationic Emulsions
|
3: Placebo Comparator
Vehicle
|
Drug: NOVA22007
Vehicle
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Novagali Pharma ( Mourad AMRANE, MD ) |
Study ID Numbers: | NVG08B112 |
Study First Received: | August 20, 2008 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00739349 |
Health Authority: | United States: Food and Drug Administration |
Dry Eye Cyclosporine |
Signs and Symptoms Cyclosporine Clotrimazole |
Miconazole Tioconazole Cyclosporins |
Anti-Infective Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antifungal Agents Physiological Effects of Drugs |
Enzyme Inhibitors Antirheumatic Agents Dermatologic Agents Immunosuppressive Agents Pharmacologic Actions |